

Number	Drug Manufacturer	Impacted 340B CE Types	Grantee Exemption	Manufacturer Using 340BESP™	Wholly Owned/Common Ownership Pharmacy Exemption	Allows CP Designation Only (No Data Required) if CE has In-House Pharmacy	Designation of Single Pharmacy if No In-House Pharmacy	CP Must be within 40 Miles of Parent	Separate Designation of LDD / Specialty Pharmacy	Submission of Claims Data to 340BESP™ Required	Multiple CP's Allowed with Claims Submission via 340BESP™	340BESP™ Claim Submission Lookback Period	Products Impacted	NDCs Listed On 340B ESP™	State Exemption	State Exemption Limits CPs to State	Policy Start Date	Policy Last Updated
1	abbvie	All CE's	No	Yes	No	No	Yes, 1 Retail & 1 Specialty for Hospitals Only	Yes	Yes	Yes	Yes, for Federal Grantees Only	45 Days	See 340BESP™ Duopa™, Imbruvica®, Venclexta® are LDD ⁵	Yes	AR, MS, MN, MO		2/1/2022	1/1/2025
2	Alkermes	All CE's	No	Yes	No	No	Yes, Wholly Owned or CP	No	No	No	No	45 Days	See 340BESP™	Yes	AR, LA, WV		7/22/2024	8/1/2024
3	AMGEN	All CE's	No	Yes	No	Yes	Yes, Wholly Owned or CP	Yes	No	Yes, if In-house Must Submit Data for CP & In-house	No	45 Days	See 340BESP™	Yes	AR, MS, MD, MO	Yes	12/31/2021	8/28/2024
4	astellas	Hospitals	Yes	Yes	No	No	Yes	No	Yes, Xtandi®	No	No	N/A	Xtandi® & Myrbetriq® RxS extracts NDCs from Medi-Span	No	AR, LA, MS, MD		9/1/2023	10/15/2024
5	AstraZeneca	All CE's	No	Yes	No	No	Yes	No	No	Yes	No	45 Days	See 340BESP™	Yes			10/1/2020	10/1/2024
6	BAUSCH+Health	All CE's	No	Yes	No	No	Yes	Yes	No	No	No	45 Days	See 340BESP™	Yes	AR	Yes	8/1/2022	3/12/2024
7	BAUSCH+LOMB	All CE's	No	Yes	No	No	Yes	Yes	No	No	No	45 Days	See 340BESP™	Yes			7/1/2024	
8	BAYER	All CE's	No	Yes	No	No	Yes	Yes	Yes, for drug Adempas®	Yes	No	45 Days	See 340BESP™ Adempas is LDD ⁵	Yes	AR	Yes	3/1/2023	10/1/2024
9	Biogen	All CE's	No	Yes	No	No	Yes, 1 for Avonex®, Plegridy® and 1 Zurzuvae®	Yes	Yes, Zurzuvae®	Yes	No	45 Days	Avonex®, Plegridy® and Zurzuvae®	Yes	AR, KS, LA, MD, MN, MS, WV, MO	Yes	2/1/2023	1/20/2025
10	Boehringer Ingelheim	All CE's	No	Yes	No	No	Yes, Wholly Owned or CP with Data Required	Yes	Yes, Specialty or Wholly Owned for drug OFEV®	Yes	No	45 Days	See 340BESP™	Yes	AR, LA, MO, WV		8/1/2021	12/2/2024
11	Bristol Myers Squibb	All CE's	No	Yes	No	No	Yes, 1 for IMiD drugs, 1 for non-IMiD drugs and 1 for Camzyos®, 1 for Krazati®	No	Yes	Yes	No	60 Days for IMiDs 14 Days for All Other Products	See 340BESP™ & Policy	Yes, Not All NDCs Listed	AR, MD, MS	Yes	3/1/2022	10/01/2024
12	Eisai	Hospitals	Yes	Yes	No	No	Yes, Wholly Owned or CP	No	Yes	No	No	N/A	NDCs per Manufacturer's Policy	No	AR, LA		11/1/2023	
13	EMD SERONO	All CE's	No	Yes	No	No	Yes, if No In-house	Yes	Yes, for Serostim®	No	No	N/A	NDCs per Manufacturer's Policy	No	AR	Yes	3/1/2023	10/1/2024
14	EXELIXIS	Hospitals	Yes	Yes	Yes, with Data Submission	No	Only, if No Wholly Owned	No	N/A - Policy only applies to LDD Products	Yes	Yes	45 Days	Cometriq® and Cabometyx®, See 340BESP™	Yes			7/6/2022	7/1/2024
15	Genentech <small>A Member of the Roche Group</small>	Hospitals	Yes	Yes	No	No	Yes	No	No	No	No	N/A	See 340BESP™	Yes	AR		5/1/2024	
16	GILEAD	All CE's	No	Yes	No	No	Yes, Wholly Owned or CP	No	No	No	Yes	45 Days	See 340BESP™, Hepatitis C products Epclusa®, Harvoni®, Sovaldi®, Vosevi®	Yes	AR ⁸		5/2/2022	1/30/2024
17	GlaxoSmithKline	All CE's	No	Yes	Yes	No	Yes, but not if Wholly Owned Exemption	No	Yes	No	No	N/A	NDCs per Manufacturer's Policy	No	AR, KS, LA, MD, MN, MS, WV, MO	Yes	4/1/2022	10/1/2024
18	Incyte	Hospitals	Yes	Yes	No	No	Yes, Wholly Owned or CP	No	No	No	No	N/A	Opzelura®, See 340BESP™	Yes			10/16/23	
19	Jazz Pharmaceuticals	Hospitals	Yes	Yes	No	No	Yes, Wholly Owned or CP	No	No	No	No	N/A	Epidiolex®, NDCs per manufacturer's latest policy	No	AR, KS, LA, MD, MN, MS, WV	Yes	10/9/2023	10/15/2024
20	Johnson & Johnson	Hospitals	Yes	Yes	No	Yes, Wholly Owned or CP, Data from In-House Required	Yes, Wholly Owned or CP with Data Required	Yes	Yes, PAH LDD Drugs	Yes	No	45 Days	See 340BESP™, PAH LDD ⁵ Drugs	Yes	AR ⁸ , MD ⁹ , WV ⁹	Yes	5/2/2022	9/3/2024
21	Lilly	All CE's	No	Yes	No	No	Yes, Wholly Owned or CP	No	No	Yes	Yes, (Insulin 340B Cost Must be Passed to Patient. No Mark-up for CE or Pharmacy.)	45 Days	See 340BESP™	Yes	AR		9/1/2020	7/1/2024
22	Liquidia	All CE's	No	Yes	No	No	Yes, Single Accredo or Caremark/CVS Specialty	No	No	Yes	No	45 Days	Yutrepia™ Not Currently FDA Approved	Yes	AR		4/1/2024	
23	MERCK	Hospitals, CH/CHC	Yes, Except CH/CHC	Yes	No	No	Yes, Wholly Owned or CP	Yes	No	No	No	45 Days	See 340BESP™	Yes	AR ⁸ , KS ⁹ , LA ⁹ , MD ⁹ , MN ⁹ , MS ⁹ , WV, MO ⁹		9/1/2021	8/1/2024
24	NOVARTIS	Hospitals	Yes	Yes	No	No	Yes, Wholly Owned or CP (No Central Fill)	No	No	Yes	No	45 Days	See 340BESP™	Yes	AR, MD, MS, MN, LA		11/16/2020	1/1/2025
25	novo nordisk	All CE's	No	Yes	Yes, Hospitals Unlimited with Data Submission	Yes, 2 Pharmacies	Yes, 2 Pharmacies	No	Yes	No	Yes, for Federal Grantees	45 Days	See 340BESP™	Yes	AR ⁸		1/1/2021	7/1/2024
26	ORGANON	Hospitals, CH/CHC	Yes, Except CH/CHC	Yes	No	No	Yes, Wholly Owned or CP with Data Required	No	No	Yes	No	45 Days	See 340BESP™	Yes	AR ⁸ , KS ⁹ , LA ⁹ , MD ⁹ , MN ⁹ , MS ⁹ , WV, MO ⁹		7/1/2023	12/1/2024
27	Pfizer	Hospitals	Yes	Yes	Yes, Oral Oncology & Vyndamax® and Vyndaqel®	No	Yes	No	Yes	No	Yes, Oral Oncology & Vyndamax® and Vyndaqel®	45 Days	See 340BESP™	Yes	AR, KS, MD, MN, MS, WV, MO		3/1/2022	8/28/2024
28	SANDOZ	Hospitals	Yes	Yes	Yes	No	Yes, Data Required	Yes	No	Yes	No	Not Defined	See 340BESP™	Yes	AR, LA		12/1/2023	7/1/2024
29	sanofi	CAH, DSH, RRC, SCH & CH/CHC	Yes, Except CH/CHC	Yes	No	No	Yes, Wholly Owned or CP with Data Required for CAH, DSH, RRC, SCH	No	No	Yes, for CAH, DSH, RRC, SCH	No	45 Days	See 340BESP™	Yes	AR, KS, MD ⁹ , MS ⁹ , WV, MO ⁹	Yes	10/1/2020	9/23/2024
30	sobi	All CE's	No	Yes	No	No	Yes, Wholly Owned or CP	Yes	No	No	No	N/A	Doptelet®, Kineret®, and Vonjo®. NDCs from Medi-Span	No			7/1/2024	
31	Sumitomo Pharma	All CE's	No	Yes	Yes, for Orgovyx®	No	Yes	Yes	Yes, for Orgovyx®	No	No	45 Days	See 340BESP™	Yes	AR ⁸ , KS ⁹ , LA ⁹ , MD ⁹ , MN ⁹ , MS ⁹ , WV, MO ⁹		5/1/2024	8/28/2024
32	Takeda	Hospitals	Yes	Yes	Yes, with Data Submission	No	Yes, Wholly Owned or CP with Data Required	Yes	Yes	Yes	No	45 Days	See 340BESP™	Yes	AR		1/22/2024	3/22/2024
33	teva	Hospitals	Yes	Yes	No	No	Yes, Wholly Owned or CP with Data Required	Yes	No	Yes	No	45 Days	See 340BESP™	Yes	AR, LA		7/5/2023	5/20/2024
34	ucb	All CE's	No	Yes	No	No	Yes, Wholly Owned or CP with Data Required for Hospitals	No	No	Yes (Hospitals Only)	No	Not Defined	See 340BESP™	Yes	AR, WV		12/13/2021	10/2/2023
35	United Therapeutics CORPORATION	All CE's	No	Yes	No	Yes	Yes	No	No	Yes	Yes	Not Defined	All Drugs Except Adcirca®, See 340BESP™	Yes			11/20/2020	12/1/2021
36	VERTEX	Hospitals	Yes	Yes	No	No	Yes, Wholly Owned or CP	No	No	No	No	N/A	See 340BESP™	Yes	AR, KS, LA, MD, MN, MS, WV, MO		7/1/2024	8/28/2024
37	VIATRIS	Hospitals, CH/CHC	Yes, Except CH/CHC	Yes	No	No	Yes, Wholly Owned or CP	No	No	No	No	N/A	NDCs from Medi-Span	No	AR, KS, LA, MD, MN, MS, WV	Yes	8/1/2024	8/28/2024

Key Terms	Definition
Grantee Exemption	Grantee exemption means that the drug manufacturer policy does not apply to federal grantees. Federal grantee covered entities are non-hospital covered entities described in sections 340B(a)(4)(A) through (K) of the PHSA which include entities that receive certain Federal grants, Federal contracts, Federal designations, or establish Federal projects.
Wholly Owned/Common Ownership	Pharmacies registered as contract pharmacies which are wholly owned by a 340B covered entity or have common ownership with a 340B covered entity.
CP	CP stands for Contract Pharmacy.
In-house	Pharmacies which are owned by the 340B covered entity but not registered as a contract pharmacy. The pharmacy shipping address should appear on the 340B OPASIS database under shipping addresses.
LDD	LDD stands for limited distribution drug. A limited distribution drug is a specialty drug which the pharmaceutical manufacturer has limited the number of specialty pharmacies that have access to the drug.
Lookback Period	Once 340B pricing is restored for a specific contract pharmacy, the covered entity may then place a replenishment order for those qualified claims that adhere to a pharmaceutical manufacturer's lookback policy (e.g. claims with a fill date that occurred within the 45 days prior to the data submission).
State Exemption	Manufacturers' policy specifically defines the policy does not apply in a State(s). AR = Arkansas, KS = Kansas, LA = Louisiana, MD = Maryland, MN = Minnesota, MS = Mississippi, MO = Missouri, WV = West Virginia.
State Exemption Limitation	CE required to submit data via 340B ESP™ or required to submit data via 340B ESP™ for 340B pricing access at all contract pharmacies.
State Exemption Pharmacy Limit	Manufacturers' policy limits the exclusion only to pharmacies in the CE's state.